ABSTRACT
BackgroundHealthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses.AimWe used data from a prospective influenza vaccine effectiveness study in HCP to quantify the incidence of acute respiratory infections (ARI) and their associated presenteeism and absenteeism.MethodsAt the start and end of each season, HCP at two Israeli hospitals provided serum to screen for antibodies to influenza virus using the haemagglutination inhibition assay. During the season, active monitoring for the development of ARI symptoms was conducted twice a week by RT-PCR testing of nasal swabs for influenza and respiratory syncytial virus (RSV). Workplace presenteeism and absenteeism were documented. We calculated incidences of influenza- and RSV-associated ARI and applied sampling weights to make estimates representative of the source population.ResultsThe median age of 2,505 participating HCP was 41 years, and 70% were female. Incidence was 9.1 per 100 person-seasons (95%â¯CI:â¯5.8-14.2) for RT-PCR-confirmed influenza and 2.5 per 100 person-seasons (95%â¯CI:â¯0.9-7.1) for RSV illness. Each season, 18-23% of unvaccinated and influenza-negative HCP seroconverted. The incidence of seroconversion or RT-PCR-confirmed influenza was 27.5 per 100 person-seasons (95%â¯CI:â¯17.8-42.5). Work during illness occurred in 92% (95%â¯CI:â¯91-93) of ARI episodes, absence from work in 38% (95%â¯CI:â¯36-40).ConclusionInfluenza virus and RSV infections and associated presenteeism and absenteeism were common among HCP. Improving vaccination uptake among HCP, infection control, and encouraging sick HCP to stay home are important strategies to reduce ARI incidence and decrease the risk of in-hospital transmission.
Subject(s)
Absenteeism , Health Personnel , Influenza, Human , Presenteeism , Respiratory Syncytial Virus Infections , Seasons , Humans , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/virology , Influenza, Human/epidemiology , Influenza, Human/virology , Influenza, Human/diagnosis , Influenza, Human/prevention & control , Female , Incidence , Male , Health Personnel/statistics & numerical data , Israel/epidemiology , Adult , Presenteeism/statistics & numerical data , Middle Aged , Prospective Studies , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Respiratory Syncytial Viruses/isolation & purification , Respiratory Syncytial Virus, Human/isolation & purification , Respiratory Syncytial Virus, Human/genetics , Occupational Exposure/statistics & numerical data , Hemagglutination Inhibition TestsABSTRACT
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
Subject(s)
COVID-19 , Influenza, Human , Pandemics , Respiratory Syncytial Virus Infections , SARS-CoV-2 , World Health Organization , Humans , COVID-19/epidemiology , Israel/epidemiology , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/diagnosis , Influenza, Human/epidemiology , Influenza, Human/diagnosis , Sentinel Surveillance , Laboratories, Hospital/statistics & numerical data , Respiratory Syncytial Virus, Human/isolation & purification , Population Surveillance/methodsABSTRACT
BACKGROUND: The rapid transmission and high pathogenicity of respiratory viruses significantly impact the health of both children and adults. Extracting and detecting their nucleic acid is crucial for disease prevention and treatment strategies. However, current extraction methods are laborious and time-consuming and show significant variations in nucleic acid content and purity among different kits, affecting detection sensitivity and efficiency. Our aim is to develop a novel method that reduces extraction time, simplifies operational steps, and ensures high-quality acquisition of respiratory viral nucleic acid. METHODS: We extracted respiratory syncytial virus (RSV) nucleic acid using reagents with different components and analyzed cycle threshold (Ct) values via quantitative real-time polymerase chain reaction (qRT-PCR) to optimize and validate the novel lysis and washing solution. The performance of this method was compared against magnetic bead, spin column, and precipitation methods for extracting nucleic acid from various respiratory viruses. The clinical utility of this method was confirmed by comparing it to the standard magnetic bead method for extracting clinical specimens of influenza A virus (IAV). RESULTS: The solution, composed of equal parts glycerin and ethanol (50% each), offers an innovative washing approach that achieved comparable efficacy to conventional methods in a single abbreviated cycle. When combined with our A Plus lysis solution, our novel five-minute nucleic acid extraction (FME) method for respiratory viruses yielded superior RNA concentrations and purity compared to traditional methods. FME, when used with a universal automatic nucleic acid extractor, demonstrated similar efficiency as various conventional methods in analyzing diverse concentrations of respiratory viruses. In detecting respiratory specimens from 525 patients suspected of IAV infection, the FME method showed an equivalent detection rate to the standard magnetic bead method, with a total coincidence rate of 95.43% and a kappa statistic of 0.901 (P < 0.001). CONCLUSIONS: The FME developed in this study enables the rapid and efficient extraction of nucleic acid from respiratory samples, laying a crucial foundation for the implementation of expedited molecular diagnosis.
Subject(s)
RNA, Viral , Real-Time Polymerase Chain Reaction , Humans , RNA, Viral/isolation & purification , RNA, Viral/genetics , RNA, Viral/analysis , Real-Time Polymerase Chain Reaction/methods , Influenza A virus/isolation & purification , Influenza A virus/genetics , Respiratory Tract Infections/virology , Respiratory Tract Infections/diagnosis , Specimen Handling/methods , Time Factors , Viruses/isolation & purification , Viruses/genetics , Influenza, Human/diagnosis , Influenza, Human/virology , Molecular Diagnostic Techniques/methodsABSTRACT
The multiplex molecular diagnostic assays described for severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), influenza A (IAV) and B (IBV) viruses have been mainly based on real-time reaction, which limits their access to many laboratories or diagnostic institutions. To contribute to available strategies and expand access to differential diagnosis, we describe an end-point multiplex RT-PCR targeting SARS-CoV-2, IAV and IBV with simultaneous endogenous control amplification. Initially, we looked for well-established primers sets for SARS-CoV-2, IAV, IBV and RNAse P whose amplicons could be distinguished on agarose gel. The multiplex assay was then standardized by optimizing the reaction mix and cycle conditions. The limit of detection (LoD) was determined using titrated viruses (for SARS-CoV-2 and IAV) and by dilution from a pool of IBV-positive samples. The diagnostic performance of the multiplex was evaluated by testing samples with different RNAse P and viral loads, previously identified as positive or negative for the target viruses. The amplicons of IAV (146 bp), SARS-CoV-2 (113 bp), IBV (103 bp) and RNAse P (65 bp) were adequately distinguished in our multiplex. The LoD for SARS-CoV-2, IAV and IBV was 0.02 TCID50/ml, 0.07 TCID50/ml and 10-3 from a pool of positive samples, respectively. All samples positive for SARS-CoV-2 (n=70, Ct 17.2-36.9), IAV (n=53, Ct 14-34.9) and IBV (n=12, Ct 23.9-31.9) remained positive in our multiplex assay. RNAse P from negative samples (n=40, Ct 25.2-30.2) was also amplified in the multiplex. Overall, our assay is a timely and alternative tool for detecting SARS-CoV-2 and influenza viruses in laboratories with limited access to supplies/equipment.
Subject(s)
COVID-19 , Influenza A virus , Influenza B virus , Multiplex Polymerase Chain Reaction , Ribonuclease P , SARS-CoV-2 , Humans , Ribonuclease P/genetics , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Influenza A virus/isolation & purification , Influenza A virus/genetics , Influenza B virus/isolation & purification , Influenza B virus/genetics , COVID-19/diagnosis , COVID-19/virology , Multiplex Polymerase Chain Reaction/methods , Diagnosis, Differential , Influenza, Human/diagnosis , Influenza, Human/virology , Sensitivity and Specificity , Reverse Transcriptase Polymerase Chain Reaction/methods , Limit of Detection , RNA, Viral/genetics , RNA, Viral/analysisABSTRACT
Influenza (flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar clinical symptoms, complicating the diagnosis and clinical management of these critical respiratory infections. Thus, there is an urgent need for rapid on-site detection technologies that can simultaneously detect SARS-CoV-2 and influenza A viruses. Here, we have developed the first platform that combines in situ sampling with immune swabs and multichannel surface-enhanced Raman spectroscopy (SERS) for simultaneous screening of these two respiratory viruses in a single assay. A seed-mediated growth method was used to assemble a number of silver spheres on the surface of Fe3O4@SiO2 spheres, which not only creates extensive Raman hotspots but also provides numerous sites for Raman signaling molecules, enhancing the sensing sensitivity. Integrating two specific Raman signaling molecules into the nanospheres allows for the parallel detection of both viruses, improving the efficiency of SERS signal read-out. Rapid quantitative screening of both SARS-CoV-2 and H1N1 is achievable within 15 min, with detection limits of 7.76, and 8.13 pg·mL-1 for their respective target proteins. The platform demonstrated excellent performance in testing and analyzing 98 clinical samples (SARS-CoV-2:50; influenza A:48), achieving sensitivities of 88.00, and 95.83% for SARS-CoV-2 and influenza A, respectively. Pearson's correlation analysis revealed a significant correlation with the clinical CT values (P < 0.0001), underscoring the great potential of this platform for the early, rapid, and simultaneous diagnostic discrimination of multiple pathogens.
Subject(s)
COVID-19 , Influenza A virus , SARS-CoV-2 , Silver , Spectrum Analysis, Raman , Spectrum Analysis, Raman/methods , SARS-CoV-2/isolation & purification , Humans , COVID-19/diagnosis , COVID-19/virology , Silver/chemistry , Influenza A virus/isolation & purification , Silicon Dioxide/chemistry , Influenza, Human/diagnosis , Influenza, Human/virology , Metal Nanoparticles/chemistryABSTRACT
We developed and validated the Influenza Severity Scale (ISS), a standardized risk assessment for influenza, to estimate and predict the probability of major clinical events in patients with laboratory-confirmed infection. Data from the Canadian Immunization Research Network's Serious Outcomes Surveillance Network (2011/2012-2018/2019 influenza seasons) enabled the selecting of all laboratory-confirmed influenza patients. A machine learning-based approach then identified variables, generated weighted scores, and evaluated model performance. This study included 12,954 patients with laboratory-confirmed influenza infections. The optimal scale encompassed ten variables: demographic (age and sex), health history (smoking status, chronic pulmonary disease, diabetes mellitus, and influenza vaccination status), clinical presentation (cough, sputum production, and shortness of breath), and function (need for regular support for activities of daily living). As a continuous variable, the scale had an AU-ROC of 0.73 (95% CI, 0.71-0.74). Aggregated scores classified participants into three risk categories: low (ISS < 30; 79.9% sensitivity, 51% specificity), moderate (ISS ≥ 30 but < 50; 54.5% sensitivity, 55.9% specificity), and high (ISS ≥ 50; 51.4% sensitivity, 80.5% specificity). ISS demonstrated a solid ability to identify patients with hospitalized laboratory-confirmed influenza at increased risk for Major Clinical Events, potentially impacting clinical practice and research.
Subject(s)
Influenza, Human , Severity of Illness Index , Humans , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Male , Canada/epidemiology , Female , Middle Aged , Adult , Aged , Risk Assessment/methods , Young Adult , AdolescentABSTRACT
INTRODUCTION: A hunter with a history of oncology, flu-like symptoms and ring-shaped erythema was treated with doxycycline in an outpatient setting on suspicion of a tick-borne disease. After obtaining a positive Francisella tularensis serology, antibiotic treatment was continued for a total of 21 days, followed by freedom of symptoms and falling CRP, but without prompt serological follow-up. In contrast to the previously described tularemia cases in Switzerland, the article shows less pronounced local finding without palpable lymphadenopathy.
Subject(s)
Tularemia , Humans , Male , Tularemia/diagnosis , Tularemia/drug therapy , Diagnosis, Differential , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Erythema/etiology , Influenza, Human/diagnosis , Influenza, Human/complications , Francisella tularensis/isolation & purification , Middle Aged , SwitzerlandABSTRACT
INTRODUCTION: Query (Q) fever is a zoonosis caused by the bacterium Coxiella burnetii typically presenting as an influenza-like illness (ILI) with or without hepatitis. The infection may be missed by clinicians in settings of low endemicity, as the presentation is clinically not specific, and there are many more common differential diagnoses for ILI including SARS-CoV-2 infection. METHODS: Residual serum samples were retrospectively tested for Phase 1 and 2 Q fever-specific IgM, IgG, IgA antibodies by indirect immunofluorescence and C. burnetii DNA by polymerase chain reaction. They had not been previously tested for Q fever, originating from undiagnosed patients with probable ILI, aged 10-70 years and living in regional New South Wales, Australia. The results were compared with contemperaneous data on acute Q fever diagnostic tests which had been performed based on clinicians requests from a geographically similar population. RESULTS: Only one (0.2%) instance of missed acute Q fever was identified after testing samples from 542 eligible patients who had probable ILI between 2016-2023. Laboratory data showed that during the same period, 731 samples were tested for acute Q fever for clinician-initiated requests and of those 70 (9.6%) were positive. Probability of being diagnosed with Q fever after a clinician initiated request was similar regardless of the patients sex, age and the calendar year of sampling. CONCLUSION: In this sample, Q fever was most likely to be diagnosed via clinician requested testing rather than by testing of undiagnosed patients with an influenza like illness.
Subject(s)
Coxiella burnetii , Influenza, Human , Q Fever , Humans , Q Fever/diagnosis , Q Fever/epidemiology , New South Wales/epidemiology , Middle Aged , Adult , Adolescent , Male , Aged , Female , Young Adult , Child , Influenza, Human/epidemiology , Influenza, Human/diagnosis , Influenza, Human/virology , Retrospective Studies , Coxiella burnetii/genetics , Coxiella burnetii/isolation & purification , Coxiella burnetii/immunology , Antibodies, Bacterial/blood , Diagnosis, Differential , COVID-19/diagnosis , COVID-19/epidemiology , Immunoglobulin M/bloodABSTRACT
Plastic bronchitis is a relatively uncommon illness that has been reported in all age groups. This case report describes a specific manifestation of plastic bronchitis in two pediatric brothers influenced by both smoke inhalation and influenza A virus infection. The therapeutic approach mainly involved symptomatic supportive care, antiviral therapy, repeated bronchoscopic alveolar lavage, and bronchial cast removal. Eventually, both patients went into remission. Bronchoscopy proved to be helpful in diagnosing and treating these cases.
Subject(s)
Bronchitis , Bronchoscopy , Influenza, Human , Humans , Influenza, Human/complications , Influenza, Human/diagnosis , Bronchitis/diagnosis , Bronchitis/etiology , Male , Smoke Inhalation Injury/therapy , Smoke Inhalation Injury/complications , Antiviral Agents/therapeutic use , Child , Influenza A virus/isolation & purification , Bronchoalveolar LavageABSTRACT
Acute cerebellitis (AC) is often a para-infectious inflammatory process that usually presents with a variable clinical picture; often with fever, nausea, headache, altered mental status, gait abnormalities, and coordination defects. It is usually a complication of an infectious process or as a result of post-infectious autoimmune mechanisms. We report a case of a 3 year old male with influenza A who presented with an acute encephalitic picture whose course and radiologic studies demonstrate cerebellar changes strongly compatible with AC.
Subject(s)
Cerebellar Diseases , Influenza, Human , Humans , Male , Influenza, Human/complications , Influenza, Human/diagnosis , Child, Preschool , Cerebellar Diseases/diagnosis , Magnetic Resonance Imaging , Encephalitis/diagnosisABSTRACT
Background: Accurate detection of influenza virus in clinical samples requires correct execution of all aspects of the detection test. If the viral load in a sample is below the detection limit, a false negative result may be obtained. To overcome this issue, we developed a modified transport medium (MTM) for clinical sample transportation to increase viral detection sensitivity. Method: We first validated the MTM using laboratory-stocked influenza A viruses (IAVs: H1N1, H3N2, H7N3, H9N2) and influenza B viruses (IBVs: Yamagata, Victoria). We also tested clinical samples. A total of 110 patients were enrolled and a pair of samples were collected to determine the sensitivity of real-time polymerase chain reaction (RT-PCR) following MTM treatment. Result: After 24 h culturing in MTM, the viral loads were increased, represented by a 10-fold increase in detection sensitivity for H1N1, H9N2, and IBVs, a 100-fold increase for H3N2, and a 1,000-fold increase for H7N3. We further tested the effects of MTM on 19 IAV and 11 IBV stored clinical samples. The RT-PCR results showed that the positive detection rate of IAV samples increased from 63.16% (12/19) without MTM culturing to 78.95% (15/19) after 48 h culturing, and finally 89.47% (17/19) after 72 h culturing. MTM treatment of IBV clinical samples also increased the positive detection rate from 36.36% (4/11, 0 h) to 63.64% (7/11, 48 h) to 72.73% (8/11, 72 h). For clinical samples detected by RT-PCR, MTM outperformed other transport mediums in terms of viral detection rate (11.81% increase, P=0.007). Conclusion: Our results demonstrated that the use of MTM for clinical applications can increase detection sensitivity, thus facilitating the accurate diagnosis of influenza infection.
Subject(s)
Influenza A virus , Influenza B virus , Influenza, Human , Sensitivity and Specificity , Specimen Handling , Viral Load , Humans , Influenza, Human/diagnosis , Influenza, Human/virology , Influenza A virus/isolation & purification , Influenza A virus/genetics , Influenza B virus/isolation & purification , Influenza B virus/genetics , Specimen Handling/methods , Real-Time Polymerase Chain Reaction/methods , Culture Media/chemistry , Middle Aged , Female , Adult , MaleABSTRACT
Acute respiratory tract infections, including influenza A (FluA), respiratory syncytial virus (RSV) infection, and COVID-19, can aggravate to levels requiring hospitalization, increasing morbidity and mortality. Identifying biomarkers for an accurate diagnosis and prognosis of these infections is a clinical need. We performed a cross-sectional study aimed to investigate the changes in circulating levels of arachidonic acid, interleukin 6 (IL-6), and C-reactive protein (CRP) in patients with FluA, RSV, or COVID-19, and to analyze the potential of these parameters as diagnosis or prognosis biomarkers. We analyzed serum samples from 172 FluA, 80 RSV, and 217 COVID-19 patients, and 104 healthy volunteers. Individuals with lung viral diseases showed reduced arachidonic acid concentrations compared to healthy people, with these differences being most pronounced in the order COVID-19 > RSV > FluA. Conversely, IL-6 and CRP levels were elevated across diseases, with IL-6 emerging as the most promising diagnostic biomarker, with areas under the curve (AUC) of the receiver operating characteristics plot higher than 0.85 and surpassing arachidonic acid and CRP. Moreover, IL-6 displayed notable efficacy in distinguishing between FluA patients who survived and those who did not (AUC = 0.80). These findings may provide useful tools for diagnosing and monitoring the severity of acute viral respiratory tract infections, ultimately improving patient outcomes.
Subject(s)
Arachidonic Acid , C-Reactive Protein , COVID-19 , Influenza, Human , Interleukin-6 , Respiratory Syncytial Virus Infections , Adult , Aged , Female , Humans , Male , Middle Aged , Arachidonic Acid/blood , Biomarkers/blood , C-Reactive Protein/analysis , COVID-19/blood , COVID-19/diagnosis , Cross-Sectional Studies , Influenza A virus , Influenza, Human/blood , Influenza, Human/diagnosis , Influenza, Human/virology , Interleukin-6/blood , Respiratory Syncytial Virus Infections/blood , Respiratory Syncytial Virus Infections/diagnosis , ROC CurveABSTRACT
Pathogenic microorganisms play a crucial role in the global disease burden due to their ability to cause various diseases and spread through multiple transmission routes. Immunity tests identify antigens related to these pathogens, thereby confirming past infections and monitoring the host's immune response. Traditional pathogen detection methods, including enzyme-linked immunosorbent assays (ELISAs) and chemiluminescent immunoassays (CLIAs), are often labor-intensive, slow, and reliant on sophisticated equipment and skilled personnel, which can be limiting in resource-poor settings. In contrast, the development of microfluidic technologies presents a promising alternative, offering automation, miniaturization, and cost efficiency. These advanced methods are poised to replace traditional assays by streamlining processes and enabling rapid, high-throughput immunity testing for pathogens. This review highlights the latest advancements in microfluidic systems designed for rapid and high-throughput immunity testing, incorporating immunosensors, single molecule arrays (Simoas), a lateral flow assay (LFA), and smartphone integration. It focuses on key pathogenic microorganisms such as SARS-CoV-2, influenza, and the ZIKA virus (ZIKV). Additionally, the review discusses the challenges, commercialization prospects, and future directions to advance microfluidic systems for infectious disease detection.
Subject(s)
SARS-CoV-2 , Humans , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Microfluidics/methods , Microfluidics/instrumentation , COVID-19/immunology , COVID-19/diagnosis , COVID-19/virology , Microfluidic Analytical Techniques/instrumentation , Microfluidic Analytical Techniques/methods , Immunoassay/methods , Zika Virus/immunology , Lab-On-A-Chip Devices , Biosensing Techniques/methods , Influenza, Human/diagnosis , Influenza, Human/immunology , Zika Virus Infection/diagnosis , Zika Virus Infection/immunologyABSTRACT
Combination COVID-19/influenza rapid tests provide a way to quickly and accurately differentiate between the two infections. The goal of this economic evaluation was to assess the cost and health benefits of a combination COVID-19/influenza Rapid Diagnostic Test (RDT) vs. current standard-of-care in the Brazilian private healthcare setting. A dual decision tree model was developed to estimate the impact of rapid differentiation of COVID-19 and influenza in a hypothetical cohort of 1,000 adults with influenza-like illness in an ambulatory healthcare setting. The model compared the use of a combination COVID-19/influenza RDT to Brazil standard diagnostic practice of a COVID-19 RDT and presumptive influenza diagnosis. Different levels of influenza prevalence were modeled with co-infection estimated as a function of the COVID-19 prevalence. Outcomes included accuracy of diagnosis, antiviral prescriptions and healthcare resource use (hospital bed days and ICU occupancy). Depending on influenza prevalence, considering 1,000 patients with influenza-like illness, a combination RDT compared to standard practice was estimated to result in between 88 and 149 fewer missed diagnoses of influenza (including co-infection), 161 to 185 fewer cases of over-diagnosis of influenza; a 24 to 34% reduction in hospital bed days and a 16 to 26% reduction in ICU days. In the base case scenario (20% influenza, 5% COVID-19), the combination RDT was estimated to result in cohort cost savings of $99. Based upon a de novo economic model, this analysis indicates that use of a combination RDT could positively impact influenza antiviral prescriptions and lower healthcare resource use.
Subject(s)
COVID-19 , Influenza, Human , Humans , COVID-19/diagnosis , Brazil/epidemiology , Influenza, Human/diagnosis , Influenza, Human/economics , Cost-Benefit Analysis , Adult , SARS-CoV-2 , COVID-19 Testing/economics , COVID-19 Testing/methods , Coinfection , Rapid Diagnostic TestsABSTRACT
Influenza A virus (IAV), a common respiratory infectious pathogen, poses a significant risk to personal health and public health safety due to rapid mutation and wide host range. To better prevent and treat IAV, comprehensive measures are needed for early and rapid screening and detection of IAV. Although traditional laboratory-based techniques are accurate, they are often time-consuming and not always feasible in emergency or resource-limited areas. In contrast, emerging point-of-care strategies provide faster results but may compromise sensitivity and specificity. Here, this review critically evaluates various detection methods for IAV from established laboratory-based procedures to innovative rapid diagnosis. By analyzing the recent research progress, we aim to address significant gaps in understanding the effectiveness, practicality, and applicability of these methods in different scenarios, which could provide information for healthcare strategies, guide public health response measures, and ultimately strengthen patient care in the face of the ongoing threat of IAV. Through a detailed comparison of diagnostic models, this review can provide a reliable reference for rapid, accurate and efficient detection of IAV, and to contribute to the diagnosis, treatment, prevention, and control of IAV.
Subject(s)
Influenza A virus , Influenza, Human , Point-of-Care Systems , Humans , Influenza A virus/isolation & purification , Influenza, Human/diagnosis , Point-of-Care Testing , Molecular Diagnostic Techniques/methods , Laboratories , AnimalsABSTRACT
OBJECTIVES: Influenza and Mycoplasma pneumoniae infections often present concurrent and overlapping symptoms in clinical manifestations, making it crucial to accurately differentiate between the two in clinical practice. Therefore, this study aims to explore the potential of using peripheral blood routine parameters to effectively distinguish between influenza and Mycoplasma pneumoniae infections. METHODS: This study selected 209 influenza patients (IV group) and 214 Mycoplasma pneumoniae patients (MP group) from September 2023 to January 2024 at Nansha Division, the First Affiliated Hospital of Sun Yat-sen University. We conducted a routine blood-related index test on all research subjects to develop a diagnostic model. For normally distributed parameters, we used the T-test, and for non-normally distributed parameters, we used the Wilcoxon test. RESULTS: Based on an area under the curve (AUC) threshold of ≥ 0.7, we selected indices such as Lym# (lymphocyte count), Eos# (eosinophil percentage), Mon% (monocyte percentage), PLT (platelet count), HFC# (high fluorescent cell count), and PLR (platelet to lymphocyte ratio) to construct the model. Based on these indicators, we constructed a diagnostic algorithm named IV@MP using the random forest method. CONCLUSIONS: The diagnostic algorithm demonstrated excellent diagnostic performance and was validated in a new population, with an AUC of 0.845. In addition, we developed a web tool to facilitate the diagnosis of influenza and Mycoplasma pneumoniae infections. The results of this study provide an effective tool for clinical practice, enabling physicians to accurately diagnose and differentiate between influenza and Mycoplasma pneumoniae infection, thereby offering patients more precise treatment plans.
Subject(s)
Influenza, Human , Mycoplasma pneumoniae , Pneumonia, Mycoplasma , Humans , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Mycoplasma/blood , Influenza, Human/diagnosis , Influenza, Human/blood , Male , Female , Mycoplasma pneumoniae/isolation & purification , Adult , Middle Aged , Diagnosis, Differential , Young Adult , Adolescent , Algorithms , Child , AgedABSTRACT
OBJECTIVES: This study evaluated relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV) vs high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of test-confirmed influenza emergency department visits and/or inpatient admissions ("ED/IP") and for IP admissions alone pooled across the 2017-2020 influenza seasons. Exploratory individual season analyses were also performed. METHODS: This retrospective test-negative design study included United States (US) adults age ≥65 years vaccinated with aTIV or HD-TIV who presented to an ED or IP setting with acute respiratory or febrile illness during the 2017-2020 influenza seasons. Test-positive cases and test-negative controls were grouped by vaccine received. The rVE of aTIV vs HD-TIV was evaluated using a combination of inverse probability of treatment weighting and logistic regression to adjust for potential confounders. RESULTS: Pooled analyses over the three seasons found no significant differences in the rVE of aTIV vs HD-TIV for prevention of test-confirmed influenza ED/IP (-2.5% [-19.6, 12.2]) visits and admissions or IP admissions alone (-1.6% [-22.5, 15.7]). The exploratory individual season analyses also showed no significant differences. CONCLUSIONS: Evidence from the 2017-2020 influenza seasons indicates aTIV and HD-TIV are comparable for prevention of test-confirmed influenza ED/IP visits in US adults age ≥65 years.
Subject(s)
Adjuvants, Immunologic , Hospitalization , Influenza Vaccines , Influenza, Human , Polysorbates , Seasons , Squalene , Vaccine Efficacy , Humans , Influenza Vaccines/immunology , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Aged , Male , Female , Hospitalization/statistics & numerical data , Retrospective Studies , Polysorbates/administration & dosage , Squalene/administration & dosage , Adjuvants, Immunologic/administration & dosage , United States/epidemiology , Aged, 80 and over , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunology , VaccinationABSTRACT
An increased risk for human infection with avian influenza A(H5N1) viruses is of concern. We developed an internally controlled, dual-target reverse transcription PCR for influenza A(H5) subtyping. This test could be used to detect influenza A(H5) in clinical samples.
Subject(s)
Influenza in Birds , Influenza, Human , Reverse Transcriptase Polymerase Chain Reaction , Humans , Animals , Influenza in Birds/virology , Influenza in Birds/diagnosis , Influenza, Human/virology , Influenza, Human/diagnosis , Reverse Transcriptase Polymerase Chain Reaction/methods , Influenza A Virus, H5N1 Subtype/genetics , Influenza A Virus, H5N1 Subtype/classification , Influenza A Virus, H5N1 Subtype/isolation & purification , Birds/virology , Multiplex Polymerase Chain Reaction/methods , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Influenza A virus/genetics , Influenza A virus/classification , Influenza A virus/isolation & purificationSubject(s)
Influenza A Virus, H5N1 Subtype , Influenza, Human , Humans , Influenza, Human/epidemiology , Influenza, Human/diagnosis , Michigan/epidemiology , Influenza A Virus, H5N1 Subtype/isolation & purification , Adult , Population Surveillance , Middle Aged , Female , Male , Adolescent , Young Adult , AgedABSTRACT
We assessed the performance of three different multiplex lateral flow assays manufactured by SureScreen, Microprofit and Goldsite which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Between 4 April and 20 October 2023, 1646 patients 6 months and older presenting to an outpatient department of a hospital in Hong Kong with ≥2 symptoms or signs of an acute respiratory illness were enrolled. The point estimates for all three multiplex tests had sensitivity >80% for influenza A and SARS-CoV-2 compared to PCR, and the tests manufactured by Microprofit and Goldsite had sensitivity >84% to detect RSV. Specificity was >97% for all three tests except for the SureScreen test which had specificity 86.2% (95% CI: 83.9% to 88.3%) for influenza A. Sensitivity was lower than reported by the manufacturers, resulting in a higher risk of false negatives. The three multiplex tests performed better in patients with high viral loads.